GlassScriptPhysician profile
Adrienne Stewart
NPI 1154454353
$102,409.33
in general payments reported to CMS, 2019-2025
23 companies · $7,268 in 2025
The $7,268 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,199 · 2020: $5,614 · 2021: $12K · 2022: $15K · 2023: $42K · 2024: $12K · 2025: $7,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $55K · Food and Beverage: $4,033 · Travel and Lodging: $2,179 · Education: $84.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $54,694.44 |
| Food and Beverage | $4,032.88 |
| Travel and Lodging | $2,179.40 |
| Education | $84.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $48,562.85 | 2019-2025 | Aklief, Epsolay, Oracea |
| Allergan, INC. | $24,776.43 | 2019-2022 | |
| Abbvie INC. | $21,641.39 | 2022-2025 | Botox |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,731.12 | 2019-2024 | Cabtreo |
| Aclaris Therapeutics, INC. | $1,031.38 | 2019 | |
| Sun Pharmaceutical Industries INC. | $922.39 | 2019-2024 | Winlevi, Absorica Ld, Ilumya |
| Epi Health, LLC | $671.84 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $384.76 | 2020-2021 | |
| Pfizer INC. | $363.05 | 2019-2022 | |
| Genzyme Corporation | $362.86 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $358.63 | 2019-2025 | Dupixent |
| Almirall LLC | $283.47 | 2019-2022 | |
| Merz North America, INC. | $264.94 | 2019-2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $224.70 | 2019-2025 | |
| Revance Therapeutics, INC. | $214.03 | 2025 | Daxxify |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $201.04 | 2019-2021 | |
| Incyte Corporation | $194.14 | 2021-2025 | Opzelura |
| Journey Medical Corporation | $95.22 | 2019 | |
| Dermira, INC. | $47.02 | 2020-2021 | |
| Biofrontera INC. | $31.59 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $16.91 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $15.26 | 2024 | Zoryve |
| Organon LLC | $14.31 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.